Sermorelin vs MOTS-c
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | MOTS-c |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. |
| Best For |
What They Have in Common
Both Sermorelin and MOTS-c are commonly used for: